Find a Medicare Part D prescription drug plan for 2027
Medicare Part D
Prescription Drug Coverage 2027
Medicare Part D GLP-1 Coverage 2027: Which Uses Plans Can Pay For
Reviewed by Russell Noga, Licensed Medicare Insurance Broker (all 50 states) — Last updated November 3, 2026
In 2027, Medicare Part D plans may cover GLP-1 drugs when they treat a medically accepted condition such as type 2 diabetes, heart risk, the liver disease MASH or sleep apnea, but plans still cannot pay for them when weight loss is the only goal. For weight loss, a separate CMS program called the Medicare GLP-1 Bridge charges a flat $50 a month and runs through December 31, 2027.
2027 by the Numbers
$50
monthly Medicare GLP-1 Bridge copay for weight-loss use through Dec. 31, 2027 (CMS)
$274
negotiated Medicare price for a 30-day supply of semaglutide starting Jan. 1, 2027 (CMS)
$2,400
2027 Part D out-of-pocket cap; Bridge copays do not count toward it (CMS)
GLP-1 is a family of drugs that copy a gut hormone to lower blood sugar and curb appetite. The group includes semaglutide (Ozempic, Rybelsus, Wegovy), tirzepatide (Mounjaro, Zepbound), dulaglutide (Trulicity), liraglutide (Victoza and its generics) and the newer tablet Foundayo (orforglipron). Each brand carries its own FDA-approved uses, and those uses decide who pays.
For 2027 there are two payment routes: your drug plan’s formulary, or the Medicare GLP-1 Bridge that sits outside it. This class overview explains both. Drug-specific detail lives on our pages for Ozempic coverage in 2027 and Wegovy coverage in 2027.
Key Takeaways
- The written diagnosis, not the drug name, decides whether a GLP-1 goes through your Part D plan or the Bridge.
- Part D law still excludes drugs used only for weight loss, and CMS did not finalize a 2024 proposal to change that.
- The Bridge covers Wegovy, Foundayo and the Zepbound KwikPen for $50 a month, but Extra Help does not lower that copay.
- Bridge spending never counts toward the $700 deductible or the $2,400 out-of-pocket cap.
- The larger BALANCE model will not launch in Medicare in January 2027, so plan-based weight-loss coverage is still on hold.
GLP-1 Drugs and the Uses Part D Can Pay For
| Brand (ingredient) | Uses a 2027 Part D plan may cover | Weight-loss route |
|---|---|---|
| Ozempic, Rybelsus (semaglutide) | Type 2 diabetes | Not part of the Bridge |
| Wegovy (semaglutide) | Lowering heart attack and stroke risk in adults with heart disease and overweight or obesity; MASH liver disease with scarring | Bridge, $50 a month |
| Mounjaro (tirzepatide) | Type 2 diabetes | Not part of the Bridge |
| Zepbound (tirzepatide) | Moderate to severe obstructive sleep apnea in adults with obesity | Bridge, KwikPen only |
| Trulicity (dulaglutide), Victoza and generic liraglutide | Type 2 diabetes | Not part of the Bridge |
| Foundayo (orforglipron) | Check the plan’s formulary | Bridge, $50 a month |
Uses reflect FDA labeling and CMS guidance as of late 2026. Formularies differ, and not all plans cover every drug or every strength.
A plan decides which of these products make its 2027 drug list, which tier they sit on and whether prior authorization applies. Two people with the same GLP-1 can face very different rules depending on the plan and area.
Why Weight Loss Alone Is Still Excluded
The law that created Part D lists a few drug categories plans may not pay for, and drugs used for weight loss or weight gain are one of them. That rule has not changed for 2027. In late 2024, CMS proposed treating obesity as a chronic disease so plans could cover these drugs, but in April 2025 the agency chose not to finalize that idea.
Diagnosis check: A plan looks at why the drug was prescribed. A semaglutide or tirzepatide claim tied only to weight management will be denied under the Part D benefit, even if the same product is on the formulary for another use.
This is why the Bridge exists. It pays for certain GLP-1s for weight reduction without making the drug a Part D benefit, so the exclusion stays in place while CMS gathers data.
Plan Formulary vs. the GLP-1 Bridge
Through your Part D plan
✔
Covered uses such as diabetes, heart risk, MASH or sleep apnea
✔
Plan sets tier, copay or coinsurance
✔
Deductible and $2,400 cap apply
✔
Extra Help can lower your share
✔
Appeals and transition fills available
Through the GLP-1 Bridge
✔
Weight reduction with diet and activity changes
✔
Flat $50 for a one-month supply
✔
Does not count toward the deductible or cap
✔
Extra Help does not apply
✔
No appeals process and no 60- or 90-day fills
CMS runs the Bridge through a central processor, so Part D sponsors do not take on the cost and do not have to opt in. Bridge drugs also cannot be spread out through the Medicare Prescription Payment Plan, according to the Medicare.gov fact sheet.
See plans in your area instantly!
Advertisement
Who Can Use the Bridge in 2027
Bridge requirements published by Medicare
✔
Age 18 or older with a standalone drug plan or a Medicare Advantage plan that includes drug coverage
✔
BMI of 35 or higher, or 30 or higher with heart failure, hard-to-control blood pressure or stage 3a or worse kidney disease
✔
BMI of 27 or higher with prediabetes, a past heart attack or stroke, or blocked arteries in the legs or arms
✔
A prior authorization form sent by the prescriber and approved by Medicare
Who is steered back to the plan: People with type 2 diabetes, moderate to severe sleep apnea or fatty liver disease cannot use the Bridge, because a Part D plan may already cover a GLP-1 for those conditions. Anyone whose plan already pays for a GLP-1 must keep getting it there.
Private fee-for-service plans, cost plans and PACE do not qualify for the Bridge. Refills of the same drug do not need a new approval, even when the dose changes.
Our 2027 Cost Math for Three GLP-1 Paths
| Path | How the year unfolds | Total for 2027 |
|---|---|---|
| Bridge, weight loss, 12 months | $50 each month; nothing applied to the cap | $600 |
| Semaglutide at $274 for diabetes, standard benefit | $274 in January and February, $182.50 in March, then $68.50 a month | About $1,347 |
| A covered brand GLP-1 billed near $1,000 a month | $775 in January, $250 a month after that | $2,400 cap reached in August, then $0 |
Our illustrative math using CMS 2027 parameters: $700 deductible, 25% coinsurance, $2,400 cap. The $1,000 figure is a round example, not a quoted price. Premiums are extra, and plans with copays or a lower deductible will differ.
$600
yearly Bridge cost
$0
Bridge dollars credited toward the cap
Aug.
month a $1,000 brand drug hits the cap
Begin Choosing your plan
Advertisement
CALL TO SPEAK WITH A LICENSED INSURANCE AGENT
Advertisement
What Changed and What Is Still Open
1
November 2025. The White House announced pricing deals with Eli Lilly and Novo Nordisk that included a $245 monthly Medicare price for their obesity drugs and a $50 copay goal.
2
July 1, 2026. The GLP-1 Bridge opened for weight-loss prescriptions.
3
Mid-2026. CMS extended the Bridge through December 31, 2027 and said BALANCE would not start in Medicare in 2027.
4
January 1, 2027. Negotiated semaglutide prices take effect for Ozempic, Rybelsus and Wegovy.
5
2028 and later. Whether plan-based weight-loss coverage arrives is not settled; CMS has not announced a start date.
Earlier announcements that described Zepbound and other GLP-1s reaching Part D plans in January 2027 were tied to BALANCE. With that model on hold for Medicare, those plans should be treated as unconfirmed until CMS publishes new guidance.
Checking a 2027 Plan Before You Enroll
Points to confirm for your GLP-1
✔
The exact brand, form and strength on the 2027 formulary
✔
Prior authorization or step therapy wording tied to your diagnosis
✔
Whether the drug falls under the deductible or a flat tier copay
✔
Your full-year estimate with every other prescription included
✔
Whether a weight-loss prescription would route to the Bridge instead
Formulary terms such as tiers and exceptions are explained in our Medicare Part D formulary 2027 guide, and the broader rules for next year are on the Medicare Part D plans 2027 hub.
The Bottom Line
The Bottom Line
GLP-1 coverage under Medicare in 2027 depends on the reason for the prescription. Diabetes, heart, liver and sleep apnea uses may be covered by your plan and count toward the $2,400 cap, while weight-loss use runs through the $50 Bridge until the end of 2027. Confirm the formulary listing and approval rules for your specific drug before the December 7 enrollment deadline.
We do not offer every plan available in your area. Any information we provide is limited to those plans we do offer in your area. Please contact Medicare.gov or 1-800-MEDICARE (TTY 1-877-486-2048) to get information on all of your options.
Frequently Asked Questions
➤ Which GLP-1 drugs does the Medicare Bridge cover?
Medicare lists Wegovy injection and tablet, Foundayo and the Zepbound KwikPen. Zepbound vials and single-dose pens are not part of the Bridge.
➤ Can my Part D plan cover a GLP-1 for prediabetes?
Not as a Part D benefit for weight reduction. Prediabetes with a BMI of 27 or higher can make a person eligible for the Bridge instead.
➤ Does the Bridge copay change in the catastrophic phase?
No. The $50 copay stays the same all year, and it is not counted toward the out-of-pocket cap, so it does not move you into the $0 phase.
➤ Is Trulicity part of the GLP-1 Bridge?
No. Trulicity is approved for type 2 diabetes, and people with diabetes are not eligible for the Bridge. A plan may cover it for diabetes.
➤ Can I get a 90-day supply through the Bridge?
No. Medicare allows only single fills of 28 or 30 days under the Bridge. Vacation overrides may be available.
➤ Will Medicare Advantage members get the Bridge?
Yes, if the Medicare Advantage plan includes drug coverage. Private fee-for-service plans, cost plans and PACE are excluded.
➤ What happens to the Bridge after 2027?
CMS has said the Bridge runs through December 31, 2027. What replaces it has not been announced, so plans for 2028 remain uncertain.
➤ Are there generic GLP-1s Part D may cover?
Yes. Generic liraglutide, the ingredient in Victoza, has been sold since 2024 and may be on 2027 formularies for type 2 diabetes, depending on the plan.
ZRN Health & Financial Services, LLC, a Texas limited liability company.
Begin Choosing your plan
Advertisement
CALL TO SPEAK WITH A LICENSED INSURANCE AGENT
Advertisement